Efimosfermin Alfa
Non-alcoholic Fatty Liver Disease
GlaxoSmithKlinePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 73/ 100
Competitive context
139 Active assets in the Non-alcoholic Fatty Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dapagliflozin Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 | BBB |
Empagliflozin Justin Ryder | Phase 4 | BBB |
Exenatide Fudan University | Phase 4 | BBB |
Metformin Xiqiao Zhou | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →